Product Description
IMP7068 is a potent and selective WEE1 inhibitor. The preliminary result of the safety, tolerability, pharmacokinetic, pharmacodynamic profiles and antitumor activity of IMP7068 in patients with advanced solid tumors in the monotherapy dose escalation part of the study was presented. Thirty-two patients were enrolled in eight dose cohorts. Median follow-up duration was 212 days, and one patient (uterine serous carcinoma) had a best overall response of partial response. The rate of treatment-related adverse event (TRAE) was 65.6%, and TRAEs were mostly grade 1–2. IMP7068 was well-tolerated, and its PK and PD profiles were consistent with WEE1 inhibition and were dose dependent. (Sourced from: http://www.impacttherapeutics.com/en/new/162.html)
Mechanisms of Action: WEE1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Impact Therapeutics, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Taiwan, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Breast Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| WEE1 | P1 |
Recruiting |
Prostate Cancer|Ovarian Cancer|Pancreatic Cancer|Breast Cancer |
2023-04-30 |
27% |
| CTR20212068 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |